Pharmaceuticals & Biotechnology Editor | 05/19/2010
The Health Protection Agency's Process & Analytical Development Group (PADG) has completed studies for an international Biopharm company to support validation of a bacterial toxin manufacturing process. The product is a therapeutic form of a botulinum toxin and was originally developed and manufactured in HPA’s GMP manufacturing facilities at Porton Down. The validation studies were on the downstream processing stages of the process using scaled down models.
Download PDF Attachment
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More